Table III.
PFS | OS | |||||||
---|---|---|---|---|---|---|---|---|
Univariate | Multivariate survival analysis | Univariate | Multivariate survival analysis | |||||
Clinicopathological characteristics | P-value | HR | 95% CI | P-value | P-value | HR | 95% CI | P-value |
Sex | 0.385 | 0.584 | ||||||
Drinking | 0.536 | 0.617 | ||||||
Smoking | 0.029 | 1.022 | 0.496–2.104 | 0.954 | 0.040 | 0.826 | 0.408–1.671 | 0.594 |
Age at diagnosis | 0.001 | 1.595 | 0.835–3.045 | 0.157 | 0.002 | 1.190 | 0.597–2.370 | 0.621 |
Tumor size | 0.019 | 1.725 | 0.936–3.176 | 0.080 | 0.016 | 1.659 | 0.860–3.198 | 0.131 |
Lymph node metastasis | <0.001 | 1.603 | 0.868–2.960 | 0.132 | 0.001 | 1.612 | 0.831–3.129 | 0.158 |
Clinical stage | <0.001 | 2.349 | 1.268–4.352 | 0.007 | <0.001 | 2.028 | 1.075–3.826 | 0.029 |
Resistin expression | 0.002 | 1.856 | 1.003–3.436 | 0.049 | 0.007 | 1.895 | 1.005–3.574 | 0.048 |
Chemoradiotherapy | <0.001 | 0.059 | 0.013–0.256 | <0.001 | <0.001 | 0.027 | 0.004–0.210 | 0.001 |
PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.